UK
LCP Health Analytics launches new Medicines Nexus tool that will be ‘game-changer’ for National Health Service data
Health analytics AI LCP news Life sciences Technology Health equity
LCP has developed a new platform, Medicines Nexus™, that will be a game-changer in understanding how medicines are used across the National Health Service (NHS) in the UK.
Using the latest cutting edge AI technology, the tool allows users to track NHS medicines usage across all GP practices and NHS hospitals, map these against health metrics, and dig deep into understanding variation in medicines use. This will be particularly helpful for stakeholders in medicines optimization and usage, such as pharma companies and Integrated Care Boards (ICB) and national commissioners.
The tool can also analyze prescription trends alongside disease prevalence and NHS performance metrics, meaning that NHS and industry stakeholders will better be able to understand variation and inequalities and ultimately help better target their research and development.
Medicines Nexus™ is a groundbreaking tool that could be a game-changer for open NHS data, making insights about how medicines are used in the NHS accessible in a way that has never been possible before. It makes analyzing the data quicker and more efficient and will be easier to share across organizations. Evolving technology has real power in the health field to give smarter insights and enhance decision making. For pharmaceutical companies, this could mean helping to better target research to support developing medicines fit for the evolving health landscape and for NHS users to give them powerful tools for medicines optimization.
Ben Bray Partner in LCP’s Health Analytics team
Medicines Nexus | Prescription analytics platform
Explore nowFeatured press
“Turning purpose into action” - LCP releases 2025 Impact Report
LCP has released its 2025 Impact Report, highlighting the actions the firm has taken across the year to play its part in building a healthier, fairer, and more resilient society.
LCP reports another year of sustainable growth driven by people, culture, and technology
LCP has announced a record income of £232 million (approx. $314 million) for the financial year 2024/25, representing a 10% increase on the previous year.
LCP Health Analytics partners with COTA to advance the use of US RWD to support HTA decision making internationally
LCP Health Analytics is partnering with COTA to explore how US real-world data (RWD) can support health technology assessments (HTA) in the United Kingdom (UK) and European Union (EU).
LCP Health Analytics launches US Access Solutions with two strategic hires
LCP’s Health Analytics practice has launched US Access Solutions, led by industry experts Kevin Patterson and Lee Ann Steadman, to support clients and drive growth in the market.